Trial Profile
Phase II combination of pemetrexed and oxaliplatin in patients with recurrent non-small cell lung cancer after failure to platinum based adjuvant chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Mar 2008 New trial record.